Phase 1 Hepatic Clinical Trials
47 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 47 trials
Recruiting
Phase 1
A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment
Liver DiseasesHepatic Insufficiency
Incyte Corporation16 enrolled4 locationsNCT07559474
Recruiting
Phase 1
A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment
Healthy VolunteersHepatic Impairment
Bristol-Myers Squibb24 enrolled3 locationsNCT07248839
Recruiting
Phase 1
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Gastric CancerHead and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)+9 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.40 enrolled3 locationsNCT07517198
Recruiting
Phase 1
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
HealthyHepatic Impairment
Boehringer Ingelheim32 enrolled3 locationsNCT07023354
Recruiting
Phase 1Phase 2
Dual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
Biliary Tract CancerCholangiocarcinomaExtrahepatic Cholangiocarcinoma+2 more
Beijing Biotech30 enrolled1 locationNCT07641036
Recruiting
Phase 1
Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
Advanced Malignancies and Hepatic Impairment
Novartis Pharmaceuticals24 enrolled5 locationsNCT07422610
Recruiting
Phase 1
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib
Hepatic Impairment
Genentech, Inc.32 enrolled4 locationsNCT07144111
Recruiting
Phase 1
A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.
Hepatic Insufficiency
Eli Lilly and Company36 enrolled3 locationsNCT07401862
Recruiting
Phase 1
Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants
Severe Hepatic ImpairmentNormal Hepatic Function
Institut de Recherches Internationales Servier (I.R.I.S.)20 enrolled3 locationsNCT07250633
Recruiting
Phase 1
A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
Hepatic Impairment
AstraZeneca28 enrolled4 locationsNCT07546760
Recruiting
Phase 1
Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer
Gallbladder CancerBiliary Tract NeoplasmsCholangiocarcinoma, Intrahepatic+2 more
Shanghai Zhongshan Hospital18 enrolled1 locationNCT07614061
Recruiting
Phase 1
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function
HealthyHepatic Impairment
Pfizer26 enrolled3 locationsNCT07269301
Recruiting
Phase 1
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
Moderate Hepatic Impairment
AstraZeneca20 enrolled2 locationsNCT07343960
Recruiting
Phase 1
A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems
HealthyHepatic Impairment
Boehringer Ingelheim44 enrolled1 locationNCT07486102
Recruiting
Phase 1
Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma
Stage III Intrahepatic Cholangiocarcinoma AJCC v8Stage IV Intrahepatic Cholangiocarcinoma AJCC v8Unresectable Intrahepatic Cholangiocarcinoma+2 more
Mayo Clinic16 enrolled1 locationNCT06058663
Recruiting
Phase 1
Radiprodil in Participants With Hepatic Impairment
Hepatic Impairment
GRIN Therapeutics, Inc.40 enrolled2 locationsNCT07457229
Recruiting
Phase 1
Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
HealthyHepatic Impairment
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany32 enrolled3 locationsNCT06997276
Recruiting
Phase 1
A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems
Hepatic Insufficiency
Boehringer Ingelheim44 enrolled3 locationsNCT06957756
Recruiting
Phase 1
The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.
Hepatic CirrhosisLiver Fibrosis
AstraZeneca12 enrolled2 locationsNCT07069725
Recruiting
Phase 1Phase 2
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Stage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Unresectable Hepatocellular Carcinoma+3 more
Mayo Clinic85 enrolled1 locationNCT03942328